{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:51:53Z","timestamp":1789685513327,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40744-024-00638-5","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T19:04:14Z","timestamp":1706814254000},"page":"227-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"11","author":[{"given":"Qin-Yi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Mei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Hong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1341-7588","authenticated-orcid":false,"given":"Sheng-Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"638_CR1","doi-asserted-by":"publisher","first-page":"1054539","DOI":"10.3389\/fimmu.2022.1054539","volume":"13","author":"T Wirth","year":"2022","unstructured":"Wirth T, Balandraud N, Boyer L, Lafforgue P, Pham T. Biomarkers in psoriatic arthritis: a meta-analysis and systematic review. Front Immunol. 2022;13:1054539.","journal-title":"Front Immunol"},{"key":"638_CR2","doi-asserted-by":"crossref","unstructured":"McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C, Helliwell PS. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open. 2022;8(1):e002074.","DOI":"10.1136\/rmdopen-2021-002074"},{"issue":"2","key":"638_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase\u00a03 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225\u201331.","journal-title":"Ann Rheum Dis"},{"key":"638_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637829","volume":"12","author":"C Schinocca","year":"2021","unstructured":"Schinocca C, Rizzo C, Fasano S, et al. Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:637829.","journal-title":"Front Immunol"},{"issue":"2","key":"638_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.4049\/jimmunol.1003986","volume":"187","author":"IE Adamopoulos","year":"2011","unstructured":"Adamopoulos IE, Tessmer M, Chao CC, et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol. 2011;187(2):951\u20139.","journal-title":"J Immunol"},{"issue":"2","key":"638_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173\u201392.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"638_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A \u00d6st\u00f6r","year":"2022","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase\u00a03 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81(3):351\u20138.","journal-title":"Ann Rheum Dis"},{"key":"638_CR8","doi-asserted-by":"crossref","unstructured":"Ostor AJK, Soliman AM, Papp KA, et al. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the phase\u00a03 trial KEEPsAKE 2. RMD Open. 2022;8(2):e002286.","DOI":"10.1136\/rmdopen-2022-002286"},{"key":"638_CR9","doi-asserted-by":"crossref","unstructured":"Merola J, McInnes I, Kavanaugh A, et al. POS1029 effects of treatment with risankizumab on minimal disease activity (MDA) and disease activity in psoriatic arthritis (DAPSA): an analysis of the KEEPsAKE-1 AND -2 Trials. Ann Rheum Dis. 2022;81:827","DOI":"10.1136\/annrheumdis-2022-eular.1362"},{"issue":"5","key":"638_CR10","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s40744-022-00474-5","volume":"9","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Kellner H, Morita A, et al. Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: results from a 76-week phase\u00a02 randomized trial. Rheumatol Ther. 2022;9(5):1361\u201375.","journal-title":"Rheumatol Ther"},{"key":"638_CR11","doi-asserted-by":"crossref","unstructured":"Borroni RG, Malagoli P, Gargiulo L, et al. Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study. Acta Derm Venereol. 2021;101(11):adv00605.","DOI":"10.2340\/actadv.v101.283"},{"issue":"6","key":"638_CR12","volume":"35","author":"G Caldarola","year":"2022","unstructured":"Caldarola G, Zangrilli A, Bernardini N, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1\u00a0year real-life study. Dermatol Ther. 2022;35(6):e15489.","journal-title":"Dermatol Ther"},{"issue":"3","key":"638_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466\u201375.","journal-title":"Br J Dermatol"},{"issue":"6","key":"638_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14144","volume":"33","author":"M Megna","year":"2020","unstructured":"Megna M, Fabbrocini G, Ruggiero A, Cinelli E. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12\/23 and\/or anti IL-23: preliminary data of a real-life 16-week retrospective study. Dermatol Ther. 2020;33(6):e14144.","journal-title":"Dermatol Ther"},{"issue":"6","key":"638_CR15","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s40744-022-00495-0","volume":"9","author":"N Thakre","year":"2022","unstructured":"Thakre N, D'Cunha R, Goebel A, Liu W, Pang Y, Suleiman AA. Population pharmacokinetics and exposure-response analyses for risankizumab in patients with active psoriatic arthritis. Rheumatol Therapy. 2022;9(6):1587\u2013603.","journal-title":"Rheumatol Therapy"},{"key":"638_CR16","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.2147\/DDDT.S167149","volume":"12","author":"IM Haugh","year":"2018","unstructured":"Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther. 2018;12:3879\u201383.","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"638_CR17","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23\/T(H) 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"638_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","volume":"79","author":"K McKeage","year":"2019","unstructured":"McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79(8):893\u2013900.","journal-title":"Drugs"},{"key":"638_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670398","volume":"12","author":"Y Ru","year":"2021","unstructured":"Ru Y, Ding X, Luo Y, et al. Adverse events associated with Anti-IL-23 agents: clinical evidence and possible mechanisms. Front Immunol. 2021;12:670398.","journal-title":"Front Immunol"},{"key":"638_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clim.2018.09.002","volume":"206","author":"CT Nguyen","year":"2019","unstructured":"Nguyen CT, Bloch Y, Skladanowska K, Savvides SN, Adamopoulos IE. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: a molecular insight. Clin Immunol. 2019;206:15\u201322.","journal-title":"Clin Immunol"},{"issue":"6","key":"638_CR21","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605\u201313.","journal-title":"J Immunol"},{"issue":"5","key":"638_CR22","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","volume":"60","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021;60(5):2109\u201321.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00638-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:34:16Z","timestamp":1709836456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00638-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00638-5","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Qin-Yi Su, Hao-Nan Zhou, Guo-Mei Xia, Rui-Yuan Zhang, Hong-Yuan Tian, Chang Su, Yu-Xin Liu, He-Yi Zhang, Ting Cheng, Yue-Hong Huo, Qian Li and Sheng-Xiao Zhang have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}